NCT01080365已完成1 期
A Single Dose Bioequivalence Study Comparing The Commercial Tablet Formulation To The Clinical Tablet Of Bosutinib In Healthy Subjects
Wyeth is now a wholly owned subsidiary of Pfizer1 个研究点 分布在 1 个国家目标入组 31 人开始时间: 2010年2月最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 31
- 试验地点
- 1
- 主要终点
- Pharmacokinetics, as measured by Cmax, AUC, tmax, t1/2
研究概览
简要总结
Study comparing 2 formulations of bosutinib in healthy subjects.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 50 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Men or women of nonchildbearing potential age 18 to 50 years
排除标准
- •Any clinically significant medical condition
研究组 & 干预措施
1
Experimental
Commercial Tablet
干预措施: SKI-606 (Bosutinib) (Drug)
2
Experimental
Clinical Tablet
干预措施: SKI-606 (Bosutinib) (Drug)
结局指标
主要结局
Pharmacokinetics, as measured by Cmax, AUC, tmax, t1/2
时间窗: 2 weeks
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
Study Comparing Two Different Tablet Formulations Of BosutinibHealthyNCT00934674Wyeth is now a wholly owned subsidiary of Pfizer30
已完成
不适用
A Single Dose Bioequivalence Study Of Neratinib In Healthy SubjectsHealthyNCT01142063Puma Biotechnology, Inc.28
已完成
1 期
Bioequivalence Study of Bosutinib Pediatric Capsule Relative to Commercial Tablet Under Fed ConditionHealthy ParticipantsNCT04549480Pfizer66
已完成
1 期
A Study to Test Bioequivalence Between One Test Formulation of Ibuprofen and Two Reference TreatmentsPainNCT01316978McNeil AB30
已完成
1 期
A Bioequivalence Study to Compare the Pharmacokinetics of Two Formulations of Siklos® in Healthy VolunteersHealthy VolunteersNCT05025072Theravia28